

23rd June 2020

Our ref: FOI 03762

Dear

Thank you for your request for information.

Your Request & Our Response

<p>1. In the past 3 months, how many metastatic melanoma patients were treated by your Trust?</p> <p>Dabrafenib Dabrafenib + Trametinib Densoumab Encorafenib + Binimetinib Ipilimumab Ipilimumab + Nivolumab Nivolumab Pembrolizumab Trametinib Vemurafenib Vemurafenib + Cobimetinib Other active systemic anti-cancer therapy Palliative care only</p>	<p>In the past 3 months the following numbers of metastatic melanoma patients were treated with:</p> <table border="1"> <tr><td>Dabrafenib</td><td>0</td></tr> <tr><td>Dabrafenib + Trametinib</td><td>0</td></tr> <tr><td>Densoumab</td><td>0</td></tr> <tr><td>Encorafenib + Binimetinib</td><td>0</td></tr> <tr><td>Ipilimumab</td><td>0</td></tr> <tr><td>Ipilimumab + Nivolumab</td><td>1</td></tr> <tr><td>Nivolumab</td><td>1</td></tr> <tr><td>Pembrolizumab</td><td>0</td></tr> <tr><td>Trametinib</td><td>0</td></tr> <tr><td>Vemurafenib</td><td>0</td></tr> <tr><td>Vemurafenib + Cobimetinib</td><td>0</td></tr> <tr><td>Other active systemic anti-cancer therapy</td><td>0</td></tr> <tr><td>Palliative care only</td><td>0</td></tr> </table>	Dabrafenib	0	Dabrafenib + Trametinib	0	Densoumab	0	Encorafenib + Binimetinib	0	Ipilimumab	0	Ipilimumab + Nivolumab	1	Nivolumab	1	Pembrolizumab	0	Trametinib	0	Vemurafenib	0	Vemurafenib + Cobimetinib	0	Other active systemic anti-cancer therapy	0	Palliative care only	0
Dabrafenib	0																										
Dabrafenib + Trametinib	0																										
Densoumab	0																										
Encorafenib + Binimetinib	0																										
Ipilimumab	0																										
Ipilimumab + Nivolumab	1																										
Nivolumab	1																										
Pembrolizumab	0																										
Trametinib	0																										
Vemurafenib	0																										
Vemurafenib + Cobimetinib	0																										
Other active systemic anti-cancer therapy	0																										
Palliative care only	0																										
<p>2. Within your health trust how many patients are currently [within the past 3 months] being treated for metastatic Non-small-cell lung cancer (NSCLC) with the following: Afatinib</p>	<p>In the past 3 months the following numbers of metastatic Non-small-cell lung cancer (NSCLC) patients were treated with:</p> <table border="1"> <tr><td>3-Weekly Carboplatin/weekly paclitaxel</td><td>1</td></tr> </table>	3-Weekly Carboplatin/weekly paclitaxel	1																								
3-Weekly Carboplatin/weekly paclitaxel	1																										

Chairman: Pearse Butler

Chief Executive: Kevin McGee (Interim)

RESEARCH MATTERS AND SAVES LIVES - TODAY'S RESEARCH IS TOMORROW'S CARE

Blackpool Teaching Hospitals is a Centre of Clinical and Research Excellence providing quality up to date care. We are actively involved in undertaking research to improve treatment of our patients. A member of the healthcare team may discuss current clinical trials with you.



Atezolizumab monotherapy or combination	Afatinib	10
Brigatinib	Alectinib (NICE Blueteq)	3
Ceretinib	Atezolizumab 3weekly (Blueteq)	3
Crizotinib	Atezolizumab Bevacizumab	
Docetaxel monotherapy or combination	Carboplatin Paclitaxel (Blueteq)	1
Erlotinib	Carboplatin Gemcitabine NSCLC	1
Gefitinib	Carboplatin Paclitaxel	
Gemcitabine	Pembrolizumab	7
Nitendanib + docetaxel	Carboplatin vinorelbine (IV)	1
Nivolumab	Carboplatin vinorelbine (oral)	4
Osimertinib	Cisplatin docetaxel	1
Paclitaxel	Cisplatin vinorelbine (IV) NSCLC	1
Pembrolizumab monotherapy	Cisplatin vinorelbine (oral)	
Pembrolizumab chemo in combination	NSCLC	5
Pembrolizumab monotherapy	Crizotinib (CDF Blueteq)	1
Pemetrexed monotherapy or combination	Denosumab	25
Ramucirumab	Docetaxel - 75mg/m2	4
Vinorelbine monotherapy or combination	Docetaxel/Nintedanib	5
Other active systemic anti-cancer therapy	Durvalumab 10mg/kg 2-weekly NSCLC	1
Palliative care only	Durvalumab 1500mg 4-weekly NSCLC	1
	Gefitinib	1
	Lorlatinib	4
	Nivolumab 240mg Flat Dose - (2years) (Blueteq)	7
	Nivolumab 480mg Flat Dose - (2years) (Blueteq) COVID-19 amendment	1
	Osimertinib (Tagrisso) (NICE Blueteq)	1
	Pembrolizumab Metastatic (3 weekly) (Blueteq)	41
	Pembrolizumab Metastatic (6 weekly) (Blueteq)	20
	Pembrolizumab, carboplatin and pemetrexed (CDF Blueteq)	32
	Pemetrexed and Carboplatin	4
	Pemetrexed and Cisplatin	2
	Pemetrexed Maintenance (NICE Blueteq)	7
	Weekly Carboplatin/paclitaxel (Single Week Cycles)	2
	XALT3 Trial-Crizotinib	1
	XALT3 Trial-X-396	1
	Zoledronic Acid (3 weekly)	1

<p>3. Out of the metastatic NSCLC patients currently [within the past 3 months] being treated, are you able to provide the number of patients being treated for Squamous Cell Non-small-cell lung cancer (SqNSCLC) with the following products?</p> <p>Afatinib Atezolizumab monotherapy or combination Brigatinib Ceretinib Crizotinib Docetaxel monotherapy or combination Erlotinib Gefitinib Gemcitabine Nitendanib + docetaxel Nivolumab Osimertinib Paclitaxel Pembrolizumab monotherapy Pembrolizumab chemo in combination Pembrolizumab monotherapy Pemetrexed monotherapy or combination Ramucirumab Vinorelbine mono or combination Other active systemic anti-cancer therapy Palliative care only</p>	<p>We do not record this information to the level of detail requested.</p>
---	--

The information in this response is provided under the terms of the Open Government Licence. Please see here for more information:

<http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>

The following link is a customer satisfaction survey if you would like to leave feedback:

<http://www.bfwh.nhs.uk/our-services/hospital-services/information-governance/foi-questionnaire/>

If you are dissatisfied with our response to your request for access to information you may ask us to carry out an internal review. You should do this by writing to:

The Information Governance Manager
 Blackpool Teaching Hospitals NHS Foundation Trust
 Blackpool Victoria Hospital
 Whinney Heys Rd
 Blackpool
 FY3 8NR

Email: bfwh.pso@nhs.net Requests for a review must be received within 40 working days following the initial response.

If you are not content with the outcome of our review, you may apply to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Wycliffe House



**Blackpool Teaching
Hospitals**
NHS Foundation Trust

Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours Sincerely,

Stephen Connor
Freedom of Information Manager